Assessing the Impact of Glucagon-like Peptide-1 and Glucagon-like Peptide-1/glucose-dependent Insulinotropic Polypeptide Receptor Agonist Shortages on Glycemic Control: A Single Center Study
Journal of Pharmacy Practice · 2026-12 · 39 (6) · 523-528
DOI: 10.1177/08971900261449175 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy Practice, online erschienen am 05.05.2026. Verfasst von Christian Dacon und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Henry Ford St. John Hospital, Detroit, MI, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents, Glycemic Control. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual GLP-1/glucose-dependent insulinotropic polypeptide receptor agonists (GLP-1/GIP RAs) effectively manage type 2 diabetes mellitus (T2DM). Recent medication shortages have impacted patient access to treatment. The objectives of this study were to evaluate the effect of incretin therapy shortages on glycemic control and adverse patient outcomes. This retrospective cohort study evaluated the impact of interruptions in therapy on patients receiving maintenance doses of incretin therapy for at least three months. Patients were excluded if they were not on adequate maintenance doses, had missing hemoglobin A1c (HbA1c) levels, discontinued therapy due to side effects or cost, or had a history of chronic glucocorticoid use or organ transplant. The primary outcome was HbA1c levels before and after therapy interruption. Secondary outcomes were the incidence of gastrointestinal issues, hyperglycemia, and hypoglycemia-related hospital/clinic visits. A total of 71 patients were included. The median therapy duration was 9 months. Patients had a baseline HbA1c of 6.9%. Following interruption, 25.4% of patients had glucose-lowering therapy additions to their regimen, 35.2% dosage adjustments, and 39.4% no changes. HbA1c increased significantly to 7.2% at 12 months ( P < 0.001). No significant differences were observed in adverse events or clinic/hospital visits ( P = 0.571 and P = 1.00). Shortages of incretin therapy significantly increased patients’ HbA1c levels up to 12 months post interruption. Long-term shortages or restrictions of these agents are likely to lead to adverse clinical outcomes. Further studies are needed to assess the outcomes of prolonged shortages or restrictions of these therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Henry Ford St. John Hospital, Detroit, MI, USA.
- Pharmacy practice, Wayne State University Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, USA.
ORCID-Profile: Pramodini Kale-Pradhan, Melissa Lipari
Zitieren
APA
Dacon, C., Kale-Pradhan, P., & Lipari, M. (2026). Assessing the Impact of Glucagon-like Peptide-1 and Glucagon-like Peptide-1/glucose-dependent Insulinotropic Polypeptide Receptor Agonist Shortages on Glycemic Control: A Single Center Study. Journal of Pharmacy Practice, 39(6), 523-528. https://doi.org/10.1177/08971900261449175
Vancouver
Dacon C, Kale-Pradhan P, Lipari M. Assessing the Impact of Glucagon-like Peptide-1 and Glucagon-like Peptide-1/glucose-dependent Insulinotropic Polypeptide Receptor Agonist Shortages on Glycemic Control: A Single Center Study. Journal of Pharmacy Practice. 2026;39(6):523-528. doi:10.1177/08971900261449175
BibTeX
@article{Dacon2026,
author = {Dacon, Christian and Kale-Pradhan, Pramodini and Lipari, Melissa},
title = {Assessing the Impact of Glucagon-like Peptide-1 and Glucagon-like Peptide-1/glucose-dependent Insulinotropic Polypeptide Receptor Agonist Shortages on Glycemic Control: A Single Center Study},
journal = {Journal of Pharmacy Practice},
year = {2026},
volume = {39},
number = {6},
pages = {523--528},
doi = {10.1177/08971900261449175}
}
EUVIMED